CD80 and neoplasm: Evidence indicates that ICIs enhance anti-tumor immunity by modulating the PD-1/PD-L1 and CTLA-4/CD80/86 pathways, strengthening tumor antigen recognition and ultimately inducing tumor cell death (Seto et al., 2019).